KR20120000393A - Peptides that bind to cyclodextrins, methods for their preparation and uses - Google Patents
Peptides that bind to cyclodextrins, methods for their preparation and uses Download PDFInfo
- Publication number
- KR20120000393A KR20120000393A KR1020100060739A KR20100060739A KR20120000393A KR 20120000393 A KR20120000393 A KR 20120000393A KR 1020100060739 A KR1020100060739 A KR 1020100060739A KR 20100060739 A KR20100060739 A KR 20100060739A KR 20120000393 A KR20120000393 A KR 20120000393A
- Authority
- KR
- South Korea
- Prior art keywords
- cyclodextrin
- peptide
- peptides
- phage
- bind
- Prior art date
Links
- 229920000858 Cyclodextrin Polymers 0.000 title claims abstract description 70
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 57
- 238000000034 method Methods 0.000 title claims abstract description 22
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 27
- 229940097362 cyclodextrins Drugs 0.000 title claims description 7
- 238000002360 preparation method Methods 0.000 title description 4
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims abstract description 41
- 239000011324 bead Substances 0.000 claims abstract description 13
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 12
- 239000003446 ligand Substances 0.000 claims abstract description 11
- 229920000642 polymer Polymers 0.000 claims abstract description 10
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 9
- 125000000524 functional group Chemical group 0.000 claims abstract description 8
- 230000008569 process Effects 0.000 claims description 7
- 102000037865 fusion proteins Human genes 0.000 claims description 3
- 108020001507 fusion proteins Proteins 0.000 claims description 3
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000001116 FEMA 4028 Substances 0.000 description 21
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 21
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 21
- 229960004853 betadex Drugs 0.000 description 21
- 238000003380 quartz crystal microbalance Methods 0.000 description 12
- 150000001413 amino acids Chemical group 0.000 description 11
- QJAOYSPHSNGHNC-UHFFFAOYSA-N octadecane-1-thiol Chemical compound CCCCCCCCCCCCCCCCCCS QJAOYSPHSNGHNC-UHFFFAOYSA-N 0.000 description 8
- 239000013545 self-assembled monolayer Substances 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 239000002502 liposome Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 239000002094 self assembled monolayer Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 241001515965 unidentified phage Species 0.000 description 4
- 108090001008 Avidin Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 125000003172 aldehyde group Chemical group 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 101710132601 Capsid protein Proteins 0.000 description 2
- 101710094648 Coat protein Proteins 0.000 description 2
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 101710125418 Major capsid protein Proteins 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- 101710141454 Nucleoprotein Proteins 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 101710083689 Probable capsid protein Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 235000001727 glucose Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- VMUZVGRNTPFTKE-UHFFFAOYSA-N octanehydrazide Chemical compound CCCCCCCC(=O)NN VMUZVGRNTPFTKE-UHFFFAOYSA-N 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000010453 quartz Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- QHVRVUNEAIFTEK-SZMVWBNQSA-N Arg-Pro-Trp Chemical compound N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O QHVRVUNEAIFTEK-SZMVWBNQSA-N 0.000 description 1
- HJRBIWRXULGMOA-ACZMJKKPSA-N Asn-Gln-Asp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O HJRBIWRXULGMOA-ACZMJKKPSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000252506 Characiformes Species 0.000 description 1
- 102100030497 Cytochrome c Human genes 0.000 description 1
- 108010075031 Cytochromes c Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- NHMRJKKAVMENKJ-WDCWCFNPSA-N Gln-Thr-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O NHMRJKKAVMENKJ-WDCWCFNPSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- KWLWZYMNUZJKMZ-IHRRRGAJSA-N Leu-Pro-Leu Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O KWLWZYMNUZJKMZ-IHRRRGAJSA-N 0.000 description 1
- DPURXCQCHSQPAN-AVGNSLFASA-N Leu-Pro-Pro Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 DPURXCQCHSQPAN-AVGNSLFASA-N 0.000 description 1
- JDBQSGMJBMPNFT-AVGNSLFASA-N Leu-Pro-Val Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(O)=O JDBQSGMJBMPNFT-AVGNSLFASA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- DEGCBBCMYWNJNA-RHYQMDGZSA-N Thr-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)[C@@H](C)O DEGCBBCMYWNJNA-RHYQMDGZSA-N 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- CVUDMNSZAIZFAE-UHFFFAOYSA-N Val-Arg-Pro Natural products NC(N)=NCCCC(NC(=O)C(N)C(C)C)C(=O)N1CCCC1C(O)=O CVUDMNSZAIZFAE-UHFFFAOYSA-N 0.000 description 1
- NHXZRXLFOBFMDM-AVGNSLFASA-N Val-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)C(C)C NHXZRXLFOBFMDM-AVGNSLFASA-N 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- -1 cyanoborohydride Chemical compound 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 108010054813 diprotin B Proteins 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 229960002143 fluorescein Drugs 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002304 glucoses Chemical class 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 108010073472 leucyl-prolyl-proline Proteins 0.000 description 1
- 238000012917 library technology Methods 0.000 description 1
- 239000013554 lipid monolayer Substances 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000013081 microcrystal Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000006557 surface reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 239000003656 tris buffered saline Substances 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 235000008979 vitamin B4 Nutrition 0.000 description 1
- 239000011579 vitamin B4 Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
본 발명은 싸이클로덱스트린 (cyclodextrin)에 결합하는 펩티드, 그의 제조방법 및 용도에 관한 것으로, 보다 구체적으로는 특정 리간드 또는 작용기와 함께 복합체를 형성하여 싸이클로덱스트린을 포함하는 센서 칩 표면이나 약물 전달용 싸이클로덱스트린 고분자에 쉽게 고정되도록 하는 펩티드, 그의 제조방법 및 용도에 관한 것이다.
The present invention relates to a peptide that binds to a cyclodextrin, a method for producing the same, and a use thereof, and more particularly, to form a complex with a specific ligand or a functional group to form a complex with a cyclodextrin, or a cyclodextrin for drug delivery including a cyclodextrin. Peptides to be easily immobilized on a polymer, methods for making and uses thereof.
싸이클로덱스트린은 글루코오스 단량체가 α-(1,4) 결합하여 고리 구조를 하고 있는 화합물로서, 글루코오스 6개가 결합한 α-싸이클로덱스트린, 7개가 결합한 β-싸이클로덱스트린, 8개가 결합한 γ-싸이클로덱스트린이 있다 (도 1). 싸이클로덱스트린의 하이드록시기는 고리의 밖으로 위치하여, 고리의 외곽은 친수성이지만, 고리의 내부는 소수성인 특성을 갖는다 (도 2). 따라서 고리 내부의 소수성을 이용해 소수성 게스트 (guest) 분자들을 결합시켜 복합체를 형성할 수 있는 특성을 지니고 있다 (도 3). Cyclodextrin is a compound in which a glucose monomer is α- (1,4) -bonded to form a ring structure, such as α-cyclodextrin to which six glucoses are bound, β-cyclodextrin to which seven are bound, and γ-cyclodextrin to which eight are bound ( 1). The hydroxyl group of the cyclodextrin is located outside of the ring, so that the outer part of the ring is hydrophilic but the inside of the ring is hydrophobic (FIG. 2). Therefore, it has the property of forming a complex by combining hydrophobic guest molecules using hydrophobicity inside the ring (FIG. 3).
이러한 싸이클로덱스트린의 특성은 치료물질의 용해도, 안정성, 생체이용성 등을 개선시키는데 이용되고 있다. 뿐만 아니라 이와 같이 치료물질과 복합체를 형성하고 있는 싸이클로덱스트린 고분자에 트랜스페린이나 엽산과 같이 암세포에 잘 결합하는 리간드를 결합시켜 표적지향형 약물을 개발한 연구결과도 보고되었다 (Bellocq et al, 2003, Bioconjugate Chem., 14, 1122; Salmaso et al., 2004, 15, 997). 또한 admantane을 결합시킨 시토크롬 c 단백질을 센서 칩 표면에 고정시키는데 싸이클로덱스트린이 사용되기도 했다 (Fragoso et al., Langmuir, 2002, 18, 5051).Such cyclodextrins have been used to improve the solubility, stability, bioavailability, etc. of therapeutic substances. In addition, the results of research on developing targeted drugs by combining ligands that bind well to cancer cells, such as transferrin and folic acid, to cyclodextrin polymers complexed with therapeutic substances have been reported (Bellocq et al, 2003, Bioconjugate Chem). , 14, 1122; Salmaso et al., 2004, 15, 997). Cyclodextrins have also been used to immobilize cytochrome c proteins bound to admantane on the sensor chip surface (Fragoso et al., Langmuir, 2002, 18, 5051).
그러나 이와 같이 단백질을 싸이클로덱스트린에 결합시키기 위해서는 해당 단백질에 admantane과 같은 소수성 게스트 분자를 화학반응을 통해 연결시켜야 한다. 그러나 이 방법으로는 admantane-단백질 복합체의 균일성을 확조하는 것이 어렵다. 반면에 싸이클로덱스트린에 결합하는 펩티드가 있다면 이 펩티드를 암호화하는 염기서열과 고정하고자 하는 단백질의 염기서열을 연결하여 하나의 융합단백질로 합성할 수 있는 장점이 있다. 뿐만 아니라 펩티드의 합성이나 변형에 관한 화학적 방법들은 매우 잘 확립되어 있기 때문에 화학적인 방법을 통해 펩티드에 리간드나 작용기를 도입하는 것도 비교적 용이하다.However, in order to bind a protein to cyclodextrin, a hydrophobic guest molecule such as admantane must be linked to the protein through a chemical reaction. However, it is difficult to increase the uniformity of the admantane-protein complex with this method. On the other hand, if there is a peptide that binds to cyclodextrin, there is an advantage that can be synthesized as a single fusion protein by connecting the base sequence encoding the peptide and the base sequence of the protein to be fixed. In addition, since chemical methods for synthesis or modification of peptides are very well established, it is relatively easy to introduce ligands or functional groups into peptides through chemical methods.
대한민국 공개특허 제2005-51686호는 ‘사이클로덱스트린-기초한 재료, 조성물 및 이의 용도’에 관한 것으로, 싸이클로덱스트린을 보유하는 선형 생체적합성 중합체 및 연결 분자를 함유하는 중합체 조성물을 기재하고 있고, 대한민국 공개특허 제2009-79199호는 ‘펩티드’에 관한 것으로, 내부로 구속된 고리 올리고펩티드에 있어서 표적 리간드에 특별하게 결합하기 위한 6개 이상의 아미노산 링을 포함하는 고리 올리고펩티드를 기재하고 있다.Republic of Korea Patent Publication No. 2005-51686 relates to 'cyclodextrin-based materials, compositions and uses thereof,' describes a polymer composition containing a linear biocompatible polymer and a linking molecule having a cyclodextrin, No. 2009-79199 relates to 'peptides' and describes ring oligopeptides comprising at least six amino acid rings for specifically binding to a target ligand in an internally bound ring oligopeptide.
그러나, 종래의 기술 중 어떠한 것도 본 발명에 기재된 바와 같은 싸이클로덱스트린에 결합하는 펩티드, 그의 제조방법 및 용도에 대하여는 기재하고 있지 않다.
However, none of the prior art describes peptides that bind to cyclodextrins as described herein, methods for their preparation and uses.
본 발명의 목적은 싸이클로덱스트린에 결합하는 펩티드를 제공하는 것이다.It is an object of the present invention to provide a peptide that binds to cyclodextrin.
또한, 본 발명의 목적은 싸이클로덱스트린에 결합하는 펩티드를 확인하는 방법을 제공하는 것이다.It is also an object of the present invention to provide a method for identifying a peptide that binds to cyclodextrin.
또한, 본 발명의 목적은 싸이클로덱스트린에 리간드나 작용기를 도입하기 위한 펩티드를 제공하는 것이다.
It is also an object of the present invention to provide a peptide for introducing a ligand or a functional group into a cyclodextrin.
본 발명에 따르면, 싸이클로덱스트린과 결합하는 LPVRPWT (CD-01), LPLTPLP (CD-02), LPPQTLI (CD-03) 또는 NQDVPLF (CD-04) 서열의 펩티드를 제공한다.According to the present invention, peptides of the LPVRPWT (CD-01), LPLTPLP (CD-02), LPPQTLI (CD-03) or NQDVPLF (CD-04) sequences that bind to cyclodextrins are provided.
본 발명에 따르면, 싸이클로덱스트린에 결합하여서 싸이클로덱스트린에 리간드나 작용기를 도입하는 것을 특징으로 하는 LPVRPWT (CD-01), LPLTPLP (CD-02), LPPQTLI (CD-03) 또는 NQDVPLF (CD-04) 서열의 펩티드를 제공한다.
According to the present invention, LPVRPWT (CD-01), LPLTPLP (CD-02), LPPQTLI (CD-03) or NQDVPLF (CD-04), characterized in that a ligand or a functional group is introduced into the cyclodextrin by binding to the cyclodextrin. Provide peptides of the sequence.
본 발명의 펩티드를 이용할 경우 싸이클로덱스트린에 리간드나 작용기를 용이하게 도입할 수 있는 효과를 얻을 수 있다.
When the peptide of the present invention is used, an effect of easily introducing a ligand or a functional group into the cyclodextrin can be obtained.
도 1은 싸이클로덱스트린의 분자 구조를 나타낸다.
도 2는 싸이클로덱스트린의 입체 구조를 나타낸다.
도 3은 싸이클로덱스트린에 guest 분자가 결합하는 반응을 나타낸다.
도 4는 섬유상 박테리오파지의 구조를 나타낸다.
도 5는 바이오패닝의 원리를 나타낸 그림이다.
도 6은 Ph.D-7 파지-펩티드 문고에서의 무작위 아미노산 서열의 구조를 나타낸다.
도 7은 본 발명에 따른 바이오패닝 방법을 나타낸다.
도 8은 Quartz crystal microbalance (QCM) 바이오센서를 이용한 펩티드들의 친화도 측정 결과를 나타낸다.
도 9는 싸이클로덱스트린 고분자 구슬과 필터를 이용한 펩티드들의 친화도 측정 결과를 나타낸다.1 shows the molecular structure of cyclodextrin.
2 shows the three-dimensional structure of the cyclodextrin.
Figure 3 shows the reaction of the guest molecule to the cyclodextrin.
Figure 4 shows the structure of the fibrous bacteriophage.
5 is a diagram illustrating the principle of biopanning.
Figure 6 shows the structure of random amino acid sequences in Ph.D-7 phage-peptide library.
7 shows a biopanning method according to the present invention.
8 shows affinity measurement results of peptides using a quartz crystal microbalance (QCM) biosensor.
9 shows affinity measurement results of peptides using cyclodextrin polymer beads and filters.
본 발명에 따르면, 파지-펩티드 문고를 검색하는 단계, 싸이클로덱스트린 고분자 구슬에 파지-펩티드 문고를 첨가하여 바이오패닝 (biopanning) 과정을 반복하는 단계, 바이오패닝 과정에서 회수된 펩티드 중 발생 빈도가 높은 펩티드의 염기 서열을 확인하는 단계를 포함하는 방법에 의해 본 발명의 펩티드를 제공한다. According to the present invention, a step of searching for a phage-peptide library, a step of repeating the biopanning process by adding a phage-peptide library to the cyclodextrin polymer beads, peptides with high frequency among the peptides recovered in the biopanning process It provides a peptide of the present invention by a method comprising the step of identifying the base sequence of.
파지-펩티드 문고 기술은 M13이나 fd와 같은 섬유상 박테리오파지 (filamentous bacteriophage)의 껍질 단백질 (coat protein)에 무작위 아미노산 서열의 펩티드를 나타낸 박테리오파지들로 이루어진 집단으로부터 특정 목표 분자에 결합하는 리간드를 검색하는 기술이다. 도 4는 섬유상 박테리오파지의 구조를 나타내는데, coat protein 가운데 protein 3의 N-말단 부분에 무작위 아미노산 서열의 펩티드를 나타낸 구조를 볼 수 있다. Phage-peptide library technology is a technique for searching for ligands that bind to a specific target molecule from a population of bacteriophages that exhibit peptides of random amino acid sequence in a coat protein of fibrous bacteriophages such as M13 or fd. . Figure 4 shows the structure of the fibrous bacteriophage, which can be seen the structure of a peptide of the random amino acid sequence in the N-terminal portion of
본 발명에 따르면, 싸이클로덱스트린에 결합하는 펩티드를 찾기 위해 무작위 아미노산이 7개인 Ph.D-7 파지-펩티드 문고를 검색하였다. Ph.D-7은 7개의 잔기로 이루어진 펩티드가 일직선으로 나열된 것이다. Ph.D-7의 무작위 아미노산 서열 부분은 도 6에 나타나 있으며 X로 표시된 부분이 무작위 서열이다.According to the present invention, a Ph.D-7 phage-peptide library with seven random amino acids was searched for a peptide that binds to cyclodextrin. Ph.D-7 is a straight line of peptides consisting of seven residues. The random amino acid sequence portion of Ph.D-7 is shown in FIG. 6 and the portion marked with X is the random sequence.
바이오패닝은 특정 목표 분자에 결합하는 파지를 찾는 방법이다. 바이오패닝 방법의 원리는 이하에 기재된 바와 같다(도 5 참고). 목표 분자가 부착되어 있는 고체 표면에 파지-펩티드 문고를 넣어 결합시킨 후 씻어내면 결합성이 있는 파지들만 남게 된다. 결합한 파지들을 다시 회수하여 숙주 박테리아에 감염시키면 같은 성질을 갖는 파지들이 증폭되고, 증폭된 파지를 이용하여 앞의 과정을 반복하게 되면 특이적으로 결합하는 파지의 비율이 높아져서 마침내는 원하는 펩티드만을 분리할 수 있게 된다. 바이오패닝을 통해 목표 분자에 결합하는 파지를 찾으면 그 파지에 표현된 펩티드의 아미노산 서열은 protein 3의 유전자인 gene 3 앞에 삽입된 DNA의 염기서열로부터 추정할 수 있다. Biopanning is a method of finding phages that bind to specific target molecules. The principle of the biopanning method is as described below (see FIG. 5). When the phage-peptide library is put on the solid surface to which the target molecule is attached and then washed, the remaining phages remain. By recovering the bound phage and infecting it with a host bacterium, phages having the same properties are amplified. When the above process is repeated using the amplified phage, the ratio of the specifically bound phage increases, finally separating only the desired peptide. It becomes possible. When the phage binds to the target molecule through biopanning, the amino acid sequence of the peptide expressed in the phage can be estimated from the base sequence of the DNA inserted before
본 발명에 따르면, 싸이클로덱스트린에 결합하는 펩티드를 찾기 위해 도 7에 나타낸 것처럼 먼저 싸이클로덱스트린 고분자 구슬에 파지-펩티드 문고를 더하여 결합시키고 원심분리를 하여 구슬만 가라앉혔다. 용액 중의 결합하지 않은 파지를 제거하고 완충용액으로 구슬을 씻어주었다. 그리고 마지막으로 구슬에 결합한 파지를 회수하여 대장균에서 증폭하였다. According to the present invention, in order to find a peptide that binds to cyclodextrin, the phage-peptide library was added to the cyclodextrin polymer beads first, as shown in FIG. Unbound phages were removed from the solution and the beads were washed with buffer. Finally, the phages bound to the beads were recovered and amplified in E. coli.
상기와 같은 바이오패닝 과정을 5회 반복한 후 마지막에 회수된 파지 가운데 10개를 무작위로 선별하여 펩티드에 대한 암호를 가지고 있는 염기서열을 결정하였다. 그 결과 발생 빈도가 높은 펩티드로 LPVRPWT (CD-01), LPLTPLP (CD-02), LPPQTLI (CD-03), NQDVPLF (CD-04) 서열이 확인되었다. 이와 같이 반복된 바이오패닝 과정을 통해 발생 빈도가 높아진 아미노산 서열은 싸이클로덱스트린에 결합하는 특성이 우수하다는 것을 의미한다. After repeating the biopanning process five times as described above, ten of the finally recovered phages were randomly selected to determine the base sequence having the code for the peptide. As a result, LPVRPWT (CD-01), LPLTPLP (CD-02), LPPQTLI (CD-03), and NQDVPLF (CD-04) sequences were identified as high incidence peptides. As described above, the amino acid sequence of which frequency is increased through repeated biopanning process means that the binding property to cyclodextrin is excellent.
상기로부터 수득된 본 발명의 펩티드는 단백질, 예컨대 항체, 호르몬 단백질, 효소 단백질 등과 융합 단백질을 형성할 수 있다. The peptides of the present invention obtained from the above can form fusion proteins such as proteins, such as antibodies, hormone proteins, enzyme proteins and the like.
또한, 본 발명의 펩티드는 싸이클로덱스트린과 결합하여 작용기나 리간드, 예컨대 fluorescein, 엽산, 비오틴 등을 도입시킬 수 있다. In addition, the peptide of the present invention can be combined with cyclodextrin to introduce functional groups or ligands such as fluorescein, folic acid, biotin and the like.
이하, 본 발명을 하기 실시예에 의해 보다 상세히 설명한다. 그러나, 본 발명의 범위가 이에 한정되는 것은 아니다.
Hereinafter, the present invention will be described in more detail by the following examples. However, the scope of the present invention is not limited thereto.
제조예Manufacturing example 1: 펩티드의 제조 1: Preparation of Peptides
고분자 구슬 형태의 β-싸이클로덱스트린 (Sigma에서 구입) 10 mg을 1.5 ml 마이크로튜브에 넣고 TBST (Tris-buffered saline + Tween-20, 50mM Tris-Cl, pH 7.5, 150mM NaCl, 0.1% Tween-20) 1 ml을 더하여 실온에서 30분간 수화시켰다. 여기에 New England Biolab에서 구입한 Ph.D-7 파지 펩티드 문고 10 μl (2×1013 pfu/ml, 2×109 independent sequences)를 더하여 실온에서 1시간 동안 흔들어주며 결합시켰다. β-싸이클로덱스트린을 가라앉힌 후 상층액을 제거하고 β-싸이클로덱스트린 구슬을 TBST로 3회 씻어주었다. 마지막으로 상층액을 제거한 후 액체 배지에서 배양한 Escherichia coli (E. coli) XL1-blue 1 ml을 튜브에 더하여 β-싸이클로덱스트린에 결합한 파지들로 E. coli를 30분간 감염시켰다. 감염된 E. coli 일부를 차례로 묽혀 top agar plate에서 배양하여 감염된 E. coli가 있던 자리에 플라크가 형성되도록 함으로써 β-싸이클로덱스트린으로부터 회수된 파지의 수를 결정하였다. 그리고 나머지 감염된 20 ml 액체 배지에 배양한 E. coli에 더하고 5시간 동안 배양하여 파지가 증폭되도록 하였다. 증폭한 후 원심분리 하여 침전에 있는 세포는 제거하고 상층액에 있는 파지를 다음 바이오패닝에 사용하였다.10 mg of β-cyclodextrin (purchased from Sigma) in the form of polymer beads was placed in a 1.5 ml microtube and TBST (Tris-buffered saline + Tween-20, 50 mM Tris-Cl, pH 7.5, 150 mM NaCl, 0.1% Tween-20) 1 ml was added and hydrated for 30 minutes at room temperature. To this was added 10 μl (2 × 10 13 pfu / ml, 2 × 10 9 independent sequences) of Ph.D-7 phage peptides purchased from New England Biolab, followed by shaking for 1 hour at room temperature. After the β-cyclodextrin was settled, the supernatant was removed and the β-cyclodextrin beads were washed three times with TBST. Finally, after removing the supernatant, 1 ml of Escherichia coli (XL) blue incubated in liquid medium was added to the tube to infect E. coli with phages bound to β-cyclodextrin for 30 minutes. The number of phages recovered from β-cyclodextrin was determined by incubating some of the infected E. coli in turn and incubating on top agar plates to form plaques in place of the infected E. coli. In addition, E. coli incubated in the remaining infected 20 ml liquid medium and incubated for 5 hours to amplify the phage. After amplification, the cells in the precipitate were removed by centrifugation, and the phage in the supernatant was used for the next biopanning.
이와 동일한 방법으로 바이오패닝을 5회 반복한 후 마지막 바이오패닝에서 얻어진 플라크들 가운데 10개를 임의로 선택하여 파지를 배양하였다. 배양된 파지로부터 DNA를 분리하고 각 DNA의 gene 3 앞에 삽입된 무작위 염기서열을 결정하여 아미노산 서열로 전환한 결과 LPVRPWT (CD-01), LPLTPLP (CD-02), LPPQTLI (CD-03), NQDVPLF (CD-04) 서열이 각각 2회씩 나타났고 AVTVMTP (CD-05)와 TDAHASV (CD-06) 서열이 각각 1회씩 나타났다. 처음 사용한 Ph.D-7 문고에는 2×109 종류의 파지가 있으며 파지의 수는 2×1012 개이기 때문에 한 종류 파지의 수는 약 1,000개가 된다. 이 가운데서 10개의 파지를 임의로 선택했을 때 동일한 파지가 두 번 선택될 확률은 2.5×10-17 으로 극히 낮다. 따라서 5회의 바이오패닝 이후에 CD-01부터 CD-04까지 네 개의 아미노산 서열이 2회씩 나타났다는 것은 그 서열을 갖는 파지들이 다른 파지들에 비해 훨씬 강하게 증폭되었다는 것을 의미한다. 그리고 이 파지들이 β-싸이클로덱스트린에 결합하는 성질을 기준으로 바이오패닝을 했을 때 강하게 증폭되었다는 사실은 이 파지들이 β-싸이클로덱스트린에 잘 결합하는 특성을 가지고 있음을 보여준다.
In the same manner, the biopanning was repeated five times, and then ten of the plaques obtained in the last biopanning were randomly selected and cultured. The DNA was isolated from the cultured phage, and the random sequencing inserted in front of
실시예 1: Example 1: 싸이클로덱스트린에On cyclodextrin 대한 친화도 평가 Affinity rating
CD-01, CD-02, CD-04 세 가지 펩티드의 β-싸이클로덱스트린에 대한 친화도를 측정하기 위해 세 가지 아미노산 서열의 카르복시 말단 부위에 두 개의 글리신 잔기와 한 개의 리신 잔기 그리고 비오틴기를 더한 펩티드를 합성하였다. 예를 들어 CD-01의 경우 LPVRPWTGGK-biotin의 구조를 갖게 된다. 그리고 합성된 세 가지 펩티드를 각각 아비딘 단백질과 결합시켜 복합체를 형성하도록 하였다. CD-01, CD-02, CD-04 peptides with two glycine residues, one lysine residue and a biotin group added to the carboxy terminus of three amino acid sequences to determine the affinity for the β-cyclodextrin of the three peptides Was synthesized. CD-01, for example, has the structure of LPVRPWTGGK-biotin. Each of the three peptides synthesized was combined with avidin protein to form a complex.
친화도를 측정하기 위한 첫 번째 방법에서는 실험실에서 제작한 Quartz Crystal Microbalance (QCM) 바이오센서를 이용하였다. QCM은 일본 크리스탈 썬라이프(Crystal Sunlife)사에서 구입하였다. 사각형인 수정미소저울 크기는 8×8 mm이고 원형인 금 전극의 직경은 5 mm이며 수정미소저울의 고유진동수는 약 10 MHz이다. 수정미소저울의 진동수는 질량 증가에 비례하여 감소하기 때문에 수정미소저울 표면에 분석 대상 물질이 결합할 수 있는 수용체가 고정되어 있으면 분석 대상물질이 결합함에 따라 주파수가 변하는 원리를 이용하여 바이오센서로 사용될 수 있다.In the first method for measuring affinity, a laboratory-manufactured Quartz Crystal Microbalance (QCM) biosensor was used. QCM was purchased from Crystal Sunlife, Japan. The size of the square quartz crystal is 8 × 8 mm, the diameter of the circular gold electrode is 5 mm, and the natural frequency of the quartz microbalance is about 10 MHz. Since the frequency of the crystal microbalance decreases in proportion to the increase in mass, if the receptor to which the analyte is bound is fixed on the surface of the microcrystal scale, the frequency changes as the analyte binds to be used as a biosensor. Can be.
수정미소저울의 전극 표면을 세척하기 위해 수정미소저울을 1분 동안 60℃ 피라냐 용액(piranha solution) (H2SO4:H2O2 = 7:3)에 담근 후 증류수와 에탄올로 헹구고 질소가스로 건조시켰다. 다음으로 1-옥타데칸티올(1-octadecanethiol , Sigma-Aldrich, USA)을 에탄올에 2mM로 녹인 용액에 수정미소저울을 넣고 12~15시간 동안 교반하여 전극 표면에 자기조립 단분자층 (self-assembled monolayer, SAM)이 형성되도록 하였다. SAM이 형성된 센서 칩을 꺼내서 에탄올로 헹구고 질소가스로 건조시킨 후 cell에 장착하였다. To clean the electrode surface of the fertilized microbalance, soak the fertilized microbalance in 60 ° C piranha solution (H 2 SO 4 : H 2 O 2 = 7: 3) for 1 minute, rinse with distilled water and ethanol and nitrogen gas. Dried over. Next, add a microcrystalline scale to a solution of 1-octadecanethiol (1-octadecanethiol, Sigma-Aldrich, USA) in 2mM in ethanol, and stir for 12-15 hours to prepare a self-assembled monolayer (self-assembled monolayer, SAM) was formed. The sensor chip formed with SAM was taken out, rinsed with ethanol, dried with nitrogen gas, and mounted in a cell.
상기 SAM과 결합시키기 위하여 디팔미토일 포스파티딜콜린(dipalmitoyl phosphatidyl cholin; DPPC)에 옥타노익 하이드라자이드를 2:1의 몰 비로 혼합하여 리포솜을 만들었다. 여기에서 DPPC는 리포솜을 형성하는 바탕지질로 사용되었고 옥타노익 하이드라자이드는 이 리포솜에 하이드라자이드 기가 나타나도록 하기 위한 기능성 작용기를 지닌 탄화수소 화합물로 사용되었다. Liposomes were prepared by mixing octanoic hydrazide in dipalmitoyl phosphatidyl cholin (DPPC) in a 2: 1 molar ratio to bind the SAM. DPPC was used here as a substrate for forming liposomes and octanoic hydrazide was used as a hydrocarbon compound with functional functional groups to cause hydrazide groups to appear on the liposomes.
상기 제조된 리포솜을 자기조립단분자층이 형성되어 있는 센서칩과 다음과 같은 방법으로 반응시켰다. 1-옥타데칸티올로 SAM을 형성한 QCM을 우물형 셀에 장착하였다. 1-옥타데칸티올로 형성된 SAM의 표면을 40 mM 옥틸 글루코시드(octyl glucoside) 100μL로 3회 씻은 후 바로 이어 즉시 리포솜 용액 100μL를 넣고 50℃에 30-60분 동안 놓아두었다. 상기 우물형 셀을 주파수 측정기에 연결하고 리포솜 용액을 제거한 후 0.1M 수산화나트륨(NaOH)을 100μL 넣고 30초 동안 놓아두었다. 그리고 인산완충식염수(phosphate buffered saline, PBS)으로 3회 세척하였다. The prepared liposomes were reacted with a sensor chip having a self-assembled monolayer formed in the following manner. QCM with SAM-formed 1-octadecanethiol was mounted in a well cell. The surface of the SAM formed of 1-octadecanethiol was washed three times with 100 μL of 40 mM octyl glucoside, followed immediately by 100 μL of liposome solution, and placed at 50 ° C. for 30-60 minutes. The well-type cell was connected to a frequency meter, the liposome solution was removed, and 100 μL of 0.1 M sodium hydroxide (NaOH) was added and left for 30 seconds. And washed three times with phosphate buffered saline (phosphate buffered saline, PBS).
β-싸이클로덱스트린 QCM 표면에 고정시키기 전에 β-싸이클로덱스트린에 산화반응을 통해 알데하이드기가 형성되도록 하였다. 알데하이드기는 하이드라지드기와 반응하여 공유결합을 형성할 수 있다. 증류수에 1.8 mg/mL이 되도록 녹인 β-싸이클로덱스트린 0.3 ml에 50 mM 소듐 m-페리오데이트 용액 0.2 mL를 섞고 어두운 곳에서 30분 동안 반응시켰다. 반응하지 않은 소듐 m-페리오데이트는 증류수에 대해 투석하여 제거하였다. Before fixation to the β-cyclodextrin QCM surface, an aldehyde group was formed by oxidation to the β-cyclodextrin. Aldehyde groups can react with hydrazide groups to form covalent bonds. 0.2 ml of 50 mM sodium m-periodate was mixed with 0.3 ml of β-cyclodextrin dissolved in distilled water at 1.8 mg / mL and reacted in a dark place for 30 minutes. Unreacted sodium m-periodate was removed by dialysis against distilled water.
자기조립단분자층과 지질 단분자층이 차례로 결합되어 있는 QCM 표면을 pH 5.5인 100mM 아세트산 소듐 완충용액으로 3회 씻은 후 소듐 m-피리오데이트로 산화시킨 β-싸이크로덱스트린을 더하여 1시간 동안 반응 시켰다. 초순수로 3회 씻은 후 이중결합의 환원을 위해 0.1M 시아노보로하이드라이드(cyanoborohydride) 100μL를 가하고 1시간 동안 반응시켜 알데하이드기를 갖는 수용체의 고정을 안정화시켰다.The QCM surface, in which the self-assembled monolayer and the lipid monolayer were in turn, was washed three times with 100 mM sodium acetate buffer at pH 5.5, and then β-cyclodextrin oxidized with sodium m-pyridate was added and reacted for 1 hour. After washing three times with ultrapure water, 100 μL of 0.1 M cyanoborohydride was added for reduction of the double bond and reacted for 1 hour to stabilize fixation of the receptor having an aldehyde group.
다음으로 앞에서 제작한 펩티드-아비딘 복합체가 QCM에 고정된 β-싸이클로덱스트린에 결합하는지 확인하기 위해 각 복합체를 아비딘 농도 기준으로 0.1 mg/ml이 되도록 묽혀 β-싸이클로덱스트린이 고정된 QCM에 주입하였다. 이 때 한 가지 복합체를 주입하여 주파수 변화를 관찰한 후에는 해리 용액 (0.2M Glycine-HCl, pH2.3 + 1% DMSO)을 주입하여 결합한 복합체를 완전히 제거한 후 다음 복합체를 주입하였다. Next, in order to check whether the peptide-avidin complex prepared above binds to β-cyclodextrin fixed to QCM, each complex was diluted to 0.1 mg / ml based on avidin concentration and injected into β-cyclodextrin-fixed QCM. At this time, after injecting one complex and observing the frequency change, a dissociation solution (0.2M Glycine-HCl, pH2.3 + 1% DMSO) was injected to completely remove the bound complex, and then the next complex was injected.
그 결과 세 가지 복합체 모두 펩티드가 없이 아비딘만 흘려보낸 것보다 주파수 변화가 더 높게 나타나 모두 β-싸이클로덱스트린에 결합하는 것을 알 수 있었다 (도 8). QCM 바이오센서에서는 주파수 변화 값이 질량 변화에 비례하기 때문에 주파수 변화가 크다는 것은 펩티드-아비딘 복합체가 많이 결합한 것을 의미하고 이는 다시 펩티드의 친화도가 높은 것을 의미한다. 따라서 세 가지 펩티드 가운데 가장 큰 주파수 변화 값을 보여준 CD-01의 친화도가 가장 높은 것으로 판단된다.
As a result, all three complexes showed higher frequency change than avidin alone without peptide and all showed binding to β-cyclodextrin (FIG. 8). In the QCM biosensor, the frequency change is proportional to the mass change, so that the large frequency change means that the peptide-avidin complex is bound, which means that the peptide has high affinity. Therefore, CD-01, which shows the highest frequency change among the three peptides, is considered to have the highest affinity.
실시예 2: Example 2: 싸이클로덱스트린에On cyclodextrin 대한 친화도 평가 Affinity rating
다른 방법으로 세 가지 펩티드가 β-싸이클로덱스트린에 결합하는 것을 확인하기 위해 실시예 1에서 사용한 펩티드를 각각 아비딘-peroxidase (Av-Prx) 복합체에 더하여 세 가지 펩티드-아비딘-peroxidase 복합체를 형성하였다. 각 복합체 10 μg을 0.4 ml PBS (phosphate-buffered saline)에 있는 β-싸이클로덱스트린 고분자 구슬 1.2 mg과 섞어 결합시키고 0.8 마이크로미터의 구멍을 갖는 필터로 걸러주었다. 이 과정에서 β-싸이클로덱스트린 구슬에 결합한 펩티드-아비딘-peroxidase 복합체는 필터에 남지만 결합하지 않은 복합체는 필터를 빠져나가 제거된다. 그리고 필터에 루미놀과 과산화수소를 더하여 peroxidase 활성에 의해 빛이 발생하도록 하였다. 여기에서 비교를 위해 β-싸이클로덱스트린 구슬만 포함하는 시료, 아비딘-peroxidase 복합체와 β-싸이클로덱스트린 구슬만 포함하는 시료, 펩티드-아비딘-peroxidase 복합체만 포함하는 시료를 만들어 동시에 실험을 수행하였다. Alternatively, the peptides used in Example 1 were added to the avidin-peroxidase (Av-Prx) complexes to form three peptide-avidin-peroxidase complexes, respectively, to confirm that the three peptides bound to β-cyclodextrin. 10 μg of each complex was mixed with 1.2 mg of β-cyclodextrin polymer beads in 0.4 ml PBS (phosphate-buffered saline) and filtered through a filter having a hole of 0.8 micrometers. In this process, peptide-avidin-peroxidase complexes bound to β-cyclodextrin beads remain in the filter, but unbound complexes exit the filter and are removed. Luminol and hydrogen peroxide were added to the filter to generate light by peroxidase activity. Here, for comparison, samples were prepared containing only β-cyclodextrin beads, samples containing only avidin-peroxidase complex and β-cyclodextrin beads, and samples containing only peptide-avidin-peroxidase complex, and the experiments were simultaneously performed.
그 결과 도 9에서 볼 수 있는 것처럼 세 가지 펩티드 모두 대조 시료보다 높은 값을 보여주었으며 특히 CD-01은 현저하게 높은 값을 보여주었다. 이는 QCM 바이오센서를 이용한 실험과 일치하는 결과이며 CD-01 펩티드가 특히 β-싸이클로덱스트린에 대해 높은 친화도를 가지고 있음을 보여준다.
As a result, as shown in Figure 9, all three peptides showed a higher value than the control sample, especially CD-01 showed a significantly higher value. This is in line with the experiments with the QCM biosensor and shows that the CD-01 peptide has a high affinity, especially for β-cyclodextrin.
본 발명은 싸이클로덱스트린을 이용한 센서 칩의 기능화나 약물 전달에 이용할 수 있다.The present invention can be used for functionalization or drug delivery of sensor chips using cyclodextrins.
<110> KANGNUNG-WONJU NATIONAL UNIVERSITY INDUSTRY ACADEMY COOPERATION GROUP <120> Cyclodextrin-binding peptides, their preparation method and their use <130> 20000 <160> 4 <170> KopatentIn 1.71 <210> 1 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> derived from phage-peptide library <400> 1 Leu Pro Val Arg Pro Trp Thr 1 5 <210> 2 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> derived from phage-peptide library <400> 2 Leu Pro Leu Thr Pro Leu Pro 1 5 <210> 3 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> derived from phage-peptide library <400> 3 Leu Pro Pro Gln Thr Leu Ile 1 5 <210> 4 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> derived from phage-peptide library <400> 4 Asn Gln Asp Val Pro Leu Phe 1 5 <110> KANGNUNG-WONJU NATIONAL UNIVERSITY INDUSTRY ACADEMY COOPERATION GROUP <120> Cyclodextrin-binding peptides, their preparation method and their use <130> 20000 <160> 4 <170> KopatentIn 1.71 <210> 1 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> derived from phage-peptide library <400> 1 Leu Pro Val Arg Pro Trp Thr 1 5 <210> 2 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> derived from phage-peptide library <400> 2 Leu Pro Leu Thr Pro Leu Pro 1 5 <210> 3 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> derived from phage-peptide library <400> 3 Leu Pro Pro Gln Thr Leu Ile 1 5 <210> 4 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> derived from phage-peptide library <400> 4 Asn Gln Asp Val Pro Leu Phe 1 5
Claims (4)
싸이클로덱스트린 고분자 구슬(bead)에 상기 파지-펩티드 문고를 첨가하여서 바이오패닝(biopanning) 과정을 반복하는 단계,
상기 단계에서 회수된 펩티드 중 발생 빈도가 높은 펩티드의 염기 서열을 확인하는 단계를 포함하는
싸이클로덱스트린에 결합하는 펩티드를 확인하는 방법.Searching for phage-peptide libraries,
Repeating the biopanning process by adding the phage-peptide library to a cyclodextrin polymer bead,
Identifying the nucleotide sequence of the peptide with high frequency among the peptide recovered in the step
How to identify peptides that bind to cyclodextrins.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020100060739A KR20120000393A (en) | 2010-06-25 | 2010-06-25 | Peptides that bind to cyclodextrins, methods for their preparation and uses |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020100060739A KR20120000393A (en) | 2010-06-25 | 2010-06-25 | Peptides that bind to cyclodextrins, methods for their preparation and uses |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020120153771A Division KR101559560B1 (en) | 2012-12-26 | 2012-12-26 | Cyclodextrin-binidng peptides, their preparation method and their use |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20120000393A true KR20120000393A (en) | 2012-01-02 |
Family
ID=45608283
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020100060739A KR20120000393A (en) | 2010-06-25 | 2010-06-25 | Peptides that bind to cyclodextrins, methods for their preparation and uses |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20120000393A (en) |
-
2010
- 2010-06-25 KR KR1020100060739A patent/KR20120000393A/en active Application Filing
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7462462B2 (en) | Peptide capable of binding to nanographite structures | |
Rachkov et al. | Towards molecularly imprinted polymers selective to peptides and proteins. The epitope approach | |
Krebber et al. | Selectively-infective phage (SIP): a mechanistic dissection of a novel in vivo selection for protein-ligand interactions | |
Günay et al. | Identification of soft matter binding peptide ligands using phage display | |
Levine et al. | Crafting precise multivalent architectures | |
TW201124726A (en) | Compositions and methods for producing coded peptoid libraries | |
Cho et al. | Targeted binding of the M13 bacteriophage to thiamethoxam organic crystals | |
EP3986465A1 (en) | Site-specific, kinetically inert conjugation of labels and/or carriers to target molecules such as his-tagged proteins via metal complex reagents | |
KR101559560B1 (en) | Cyclodextrin-binidng peptides, their preparation method and their use | |
CN111440235B (en) | Probe for capturing hirudin polypeptide and application thereof | |
KR20120000393A (en) | Peptides that bind to cyclodextrins, methods for their preparation and uses | |
CN112375754A (en) | Severe acute respiratory syndrome coronavirus 2 affinity polypeptide based on human angiotensin converting enzyme 2 | |
CN117447560A (en) | Bicyclic peptide ligands, pharmaceutical preparations, screening methods and uses targeting EGFR | |
CN104931687A (en) | Three-dimensional biological surface, preparation method thereof, three-dimensional biological chip and application of three-dimensional biological chip | |
JP2008133194A (en) | Protein adsorption inhibition substrate and use thereof | |
Hüttl et al. | Development of Peptidyl Lysine Dendrons: 1, 3‐Dipolar Cycloaddition for Peptide Coupling and Antibody Recognition | |
Kang et al. | Identification of a polymeric β-cyclodextrin-binding peptide from a phage-displayed peptide library | |
Iijima et al. | Bio-nanocapsules for oriented immobilization of DNA aptamers on aptasensors | |
KR102747013B1 (en) | Novel peptides that specifically bind to saxitoxin | |
CN108341853B (en) | Human Serum Albumin Specific Recognition Peptide and Its Application | |
JP6893359B2 (en) | New detection method for proteins or pathogens | |
KR101395398B1 (en) | Virus-microbead complex and use thereof | |
CN116199746B (en) | High affinity Trop2 targeting multi-cyclic peptide molecular framework | |
KR102734614B1 (en) | Novel peptide for specific detection of caspase-3 | |
Bowen | Detection of lipopolysaccharide pyrogens by molecularly imprinted polymers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20100625 |
|
PA0201 | Request for examination | ||
PG1501 | Laying open of application | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20120224 Patent event code: PE09021S01D |
|
AMND | Amendment | ||
E601 | Decision to refuse application | ||
PE0601 | Decision on rejection of patent |
Patent event date: 20120925 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20120224 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |
|
AMND | Amendment | ||
PX0901 | Re-examination |
Patent event code: PX09011S01I Patent event date: 20120925 Comment text: Decision to Refuse Application Patent event code: PX09012R01I Patent event date: 20120424 Comment text: Amendment to Specification, etc. |
|
PX0601 | Decision of rejection after re-examination |
Comment text: Decision to Refuse Application Patent event code: PX06014S01D Patent event date: 20121123 Comment text: Amendment to Specification, etc. Patent event code: PX06012R01I Patent event date: 20121026 Comment text: Decision to Refuse Application Patent event code: PX06011S01I Patent event date: 20120925 Comment text: Amendment to Specification, etc. Patent event code: PX06012R01I Patent event date: 20120424 Comment text: Notification of reason for refusal Patent event code: PX06013S01I Patent event date: 20120224 |
|
A107 | Divisional application of patent | ||
J201 | Request for trial against refusal decision | ||
PA0107 | Divisional application |
Comment text: Divisional Application of Patent Patent event date: 20121226 Patent event code: PA01071R01D |
|
PJ0201 | Trial against decision of rejection |
Patent event date: 20121226 Comment text: Request for Trial against Decision on Refusal Patent event code: PJ02012R01D Patent event date: 20121123 Comment text: Decision to Refuse Application Patent event code: PJ02011S01I Patent event date: 20120925 Comment text: Decision to Refuse Application Patent event code: PJ02011S01I Appeal kind category: Appeal against decision to decline refusal Appeal identifier: 2012101010888 Request date: 20121226 |
|
J301 | Trial decision |
Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20121226 Effective date: 20140627 |
|
PJ1301 | Trial decision |
Patent event code: PJ13011S01D Patent event date: 20140627 Comment text: Trial Decision on Objection to Decision on Refusal Appeal kind category: Appeal against decision to decline refusal Request date: 20121226 Decision date: 20140627 Appeal identifier: 2012101010888 |